Publications by authors named "Norihiro Nishimoto"

Claim this Profile
E
Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor antibody, in 342 Japanese patients with multicentric Castleman disease: a 3-year, prospective, observational study.
Norihiro Nishimoto, Miho Murakami, Takeshi Johkoh, Seiji Hayashi, Shiro Ohshima

Mod Rheumatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
Yoshiya Tanaka, Ayako Yamaguchi, Toshiaki Miyamoto, Kazuhide Tanimura, Hideyuki Iwai, Norihiro Nishimoto

Rheumatology (Oxford)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nationwide questionnaire survey on the prevalence of ankylosing spondylitis and non-radiographic axial spondyloarthritis in Japan.
Yuri Matsubara, Yosikazu Nakamura, Naoto Tamura, Hideto Kameda, Kotaro Otomo, Norihiro Nishimoto

Mod Rheumatol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Analysis of Glassy State Relaxation and Ostwald Ripening during Annealing Using Freeze-Drying Microscopy.
Tigran Kharatyan, Srikanth R Gopireddy, Toru Ogawa, Tatsuhiro Kodama, Norihiro Nishimoto

Pharmaceutics· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan.
Miho Murakami, Takeshi Johkoh, Seiji Hayashi, Shiro Ohshima, Masao Mizuki, Norihiro Nishimoto

Mod Rheumatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
Yoshikazu Nakaoka, Mitsuaki Isobe, Yoshiya Tanaka, Tomonori Ishii, Seido Ooka, Norihiro Nishimoto

Rheumatology (Oxford)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive factors for structural remission using abatacept: Results from the ABROAD study.
Kosaku Murakami, Masahiro Sekiguchi, Shintaro Hirata, Takao Fujii, Kiyoshi Matsui, Norihiro Nishimoto

Mod Rheumatol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence-based clinical practice guideline for adult Still's disease.
Toshihide Mimura, Yuya Kondo, Akihide Ohta, Masahiro Iwamoto, Akiko Ota, Norihiro Nishimoto

Mod Rheumatol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Yoshikazu Nakaoka, Mitsuaki Isobe, Syuji Takei, Yoshiya Tanaka, Tomonori Ishii, Norihiro Nishimoto

Ann Rheum Dis· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan.
Shino Fujimoto, Tomohiro Koga, Atsushi Kawakami, Hiroshi Kawabata, Shinichiro Okamoto, Norihiro Nishimoto

Mod Rheumatol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total Ankle Arthroplasty for Rheumatoid Arthritis in Japanese Patients: A Retrospective Study of Intermediate to Long-Term Follow-up.
Makoto Hirao, Jun Hashimoto, Hideki Tsuboi, Kosuke Ebina, Akihide Nampei, Norihiro Nishimoto

JB JS Open Access· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease.
Yasuhiro Terasaki, Soichiro Ikushima, Shoko Matsui, Akira Hebisawa, Yasunori Ichimura, Norihiro Nishimoto

Histopathology· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
Naoki Ishiguro, Tatsuya Atsumi, Masayoshi Harigai, Tsuneyo Mimori, Norihiro Nishimoto

Mod Rheumatol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.
Masahiro Sekiguchi, Takao Fujii, Kiyoshi Matsui, Kosaku Murakami, Satoshi Morita, Norihiro Nishimoto

J Rheumatol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparisons of Aluminum and Silica Elution from Various Glass Vials.
Toru Ogawa, Makoto Miyajima, Norihiro Nishimoto, Hidemi Minami, Katsuhide Terada

Chem Pharm Bull (Tokyo)· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[IL-6 inhibitors prevent bone loss and cartilage degeneration in rheumatoid arthritis].
Miho Murakami, Norihiro Nishimoto

Clin Calcium· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Atsushi Ogata, Koichi Amano, Hiroaki Dobashi, Masayuki Inoo, Tomonori Ishii, Norihiro Nishimoto

J Rheumatol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
Mareki Ohtsuji, Qingshun Lin, Keiko Nishikawa, Naomi Ohtsuji, Hideki Okazaki, Norihiro Nishimoto

Mod Rheumatol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the classification criteria for cryoglobulinaemic vasculitis.
Luca Quartuccio, Miriam Isola, Laura Corazza, Manuel Ramos-Casals, Soledad Retamozo, Norihiro Nishimoto

Rheumatology (Oxford)· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-interleukin-6 receptor antibody (MR16-1) promotes muscle regeneration via modulation of gene expressions in infiltrated macrophages.
Ryo Fujita, Fumimori Kawano, Takashi Ohira, Naoya Nakai, Tsubasa Shibaguchi, Norihiro Nishimoto

Biochim Biophys Acta· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dermoscopy of discoid lupus erythematosus: report of two cases.
Shigeki Inui, Satoshi Itami, Miho Murakami, Norihiro Nishimoto

J Dermatol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori, Takako Miyamae, Syuji Takei, Norihiro Nishimoto

J Rheumatol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Programs for continuing medical education: a session; 8. Pharmacotherapy of rheumatoid arthritis--interleukin-6 blocker made in Japan].
Norihiro Nishimoto

Nihon Naika Gakkai Zasshi· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
Norihiro Nishimoto, Koichi Amano, Yasuhiko Hirabayashi, Takahiko Horiuchi, Tomonori Ishii

Mod Rheumatol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.
Norihiro Nishimoto, Koichi Amano, Yasuhiko Hirabayashi, Takahiko Horiuchi, Tomonori Ishii

Mod Rheumatol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis